These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25105662)

  • 1. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study.
    Renke M; Lizakowski S; Tylicki L; Rutkowski P; Knap N; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Januszczyk J; Wójcik-Stasiak M; Małgorzewicz S; Woźniak M; Rutkowski B
    Adv Med Sci; 2014 Sep; 59(2):256-60. PubMed ID: 25105662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease.
    Lizakowski S; Tylicki L; Renke M; Rutkowski P; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Małgorzewicz S; Rutkowski B
    Am J Hypertens; 2012 Jun; 25(6):636-9. PubMed ID: 22357413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.
    Lizakowski S; Tylicki L; Renke M; Rutkowski P; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz E; Łysiak-Szydłowska W; Rutkowski B
    Int Urol Nephrol; 2012 Dec; 44(6):1763-70. PubMed ID: 23326865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.
    Wu MT; Tung SC; Hsu KT; Lee CT
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):271-7. PubMed ID: 23223162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M; Tylicki L; Rutkowski P; Knap N; Zietkiewicz M; Neuwelt A; Aleksandrowicz E; Łysiak-Szydłowska W; Woźniak M; Rutkowski B
    Acta Biochim Pol; 2010; 57(1):119-23. PubMed ID: 20309434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of direct renin inhibitor, aliskiren, on arterial hypertension, chronic kidney disease and cardiovascular disease: optimal pharmacotherapy.
    Morishita Y; Kusano E
    Cardiovasc Hematol Agents Med Chem; 2013 Mar; 11(1):77-82. PubMed ID: 22827288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.
    Nakamura T; Sato E; Amaha M; Kawagoe Y; Maeda S; Yamagishi S
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):122-7. PubMed ID: 21946392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
    Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of direct renin inhibitor monotherapy on proteinuria in overt diabetic nephropathy.
    Silaratana S; Sumransurp S; Duangchana S; Tasanarong A
    J Med Assoc Thai; 2012 Jan; 95 Suppl 1():S18-23. PubMed ID: 23964439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
    Fraune C; Lange S; Krebs C; Hölzel A; Baucke J; Divac N; Schwedhelm E; Streichert T; Velden J; Garrelds IM; Danser AH; Frenay AR; van Goor H; Jankowski V; Stahl R; Nguyen G; Wenzel UO
    Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1037-48. PubMed ID: 22791343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.